Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non–Small-Cell Lung Cancer

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of thoracic oncology 2013-05, Vol.8 (5), p.e41-e42
Hauptverfasser:	Rudin, Charles M., Hong, Kelvin, Streit, Michael
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Drug Resistance, Neoplasm - genetics Female Humans Imidazoles - therapeutic use Lung Neoplasms - drug therapy Lung Neoplasms - genetics MAP Kinase Signaling System - genetics Middle Aged Mutation Oximes - therapeutic use Proto-Oncogene Proteins - genetics Proto-Oncogene Proteins B-raf - genetics Proto-Oncogene Proteins p21(ras) ras Proteins - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!